Next Article in Journal
Mesenchymal Cells Support the Oncogenicity and Therapeutic Response of the Hedgehog Pathway in Triple-Negative Breast Cancer
Previous Article in Journal
Integrated Biobanking and Tumor Model Establishment of Human Colorectal Carcinoma Provides Excellent Tools for Preclinical Research
Previous Article in Special Issue
Kinase Inhibitors and Ovarian Cancer
Open AccessReview

Potential and Challenges of Aptamers as Specific Carriers of Therapeutic Oligonucleotides for Precision Medicine in Cancer

1
IRCCS SDN, 80143 Naples, Italy
2
Department of Molecular Medicine and Medical Biotechnology, “Federico II” University of Naples, Via Pansini 5, 80131 Naples, Italy
3
Percuros BV, Albinusdreef 2, 2333ZA Leiden, The Netherlands
4
Istituto di Endocrinologia ed Oncologia Sperimentale, Consiglio Nazionale delle Ricerche (CNR), 80131 Naples, Italy
5
IRCCS Neuromed—Istituto Neurologico Mediterraneo, 86077 Pozzilli (IS), Italy
*
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
Cancers 2019, 11(10), 1521; https://doi.org/10.3390/cancers11101521
Received: 20 September 2019 / Revised: 3 October 2019 / Accepted: 5 October 2019 / Published: 10 October 2019
(This article belongs to the Special Issue Targeting Solid Tumors)
Due to the progress made in the area of precision and personalized medicine in the field of cancer therapy, strategies to selectively and specifically identify target molecules causative of the diseases are urgently needed. Efforts are being made by a number of different laboratories, companies, and researchers to develop therapeutic molecules that selectively recognize the tissues and the cells of interest, exhibit few or no off-target and side effects, are non-immunogenic, and have a strong action. Aptamers, artificially selected single-stranded DNA or RNA oligonucleotides, are promising molecules satisfying many of the requirements needed for diagnosis and precision medicine. Aptamers can also couple to their native mechanism of action the delivery of additional molecules (oligonucleotides, siRNAs, miRNAs) to target cells. In this review, we summarize recent progress in the aptamer-mediated strategy for the specific delivery of therapeutic oligonucleotides. View Full-Text
Keywords: aptamers; siRNA; miRNA; RNAi; shRNA; ASO; targeted delivery; cancer therapy; diagnosis; brain tumors aptamers; siRNA; miRNA; RNAi; shRNA; ASO; targeted delivery; cancer therapy; diagnosis; brain tumors
Show Figures

Figure 1

MDPI and ACS Style

Nuzzo, S.; Roscigno, G.; Affinito, A.; Ingenito, F.; Quintavalle, C.; Condorelli, G. Potential and Challenges of Aptamers as Specific Carriers of Therapeutic Oligonucleotides for Precision Medicine in Cancer. Cancers 2019, 11, 1521.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop